- Magenta Therapeitics ( NASDAQ: MGTA ) has halted a phase 1/2 trial of MGTA-117 for acute myeloid leukemia and myelodysplastic syndrome following the death of a patients that nay be related to the candidate.
- The participant experienced a Grade 5 Serious Adverse Event, respiratory failure and cardiac arrest that resulted in death.
- Information regarding the participant had been shares with the US FDA.
- Seeking Alpha's Quant Rating views Magenta ( MGTA ) as a strong sell.
For further details see:
Magenta Therapeutics pauses leukemia trial following participant death